γH2AX and Chk1 phosphorylation as predictive pharmacodynamic biomarkers of Chk1 inhibitor-chemotherapy combination treatments

Recent developments in the use of γ -H2AX as a quantitative DNA double-strand break biomarker

(2016) Christophe E. Redon et al.   Aging-US

Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors

(2014) Edward Sausville et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Sensitization of human cancer cells to gemcitabine by the Chk1 inhibitor MK-8776: cell cycle perturbation and impact of administration schedule in vitro and in vivo

(2013) Ryan Montano et al.   BMC CANCER

Phase I, dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumours

(2013) Takashi Seto et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Chk1 inhibition in p53-deficient cell lines drives rapid chromosome fragmentation followed by caspase-independent cell death

(2013) Christopher J Del Nagro et al.   CELL CYCLE

Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor

(2013) Constance King et al.   INVESTIGATIONAL NEW DRUGS

Combination Drug Scheduling Defines a "Window of Opportunity" for Chemopotentiation of Gemcitabine by an Orally Bioavailable, Selective ChK1 Inhibitor, GNE-900

(2013) E. Blackwood et al.   MOLECULAR CANCER THERAPEUTICS

Identification of Preferred Chemotherapeutics for Combining with aCHK1Inhibitor

(2013) Yang Xiao et al.   MOLECULAR CANCER THERAPEUTICS

Death of p53-defective cells triggered by forced mitotic entry in the presence of DNA damage is not uniquely dependent on Caspase-2 or the PIDDosome

(2013) C Manzl et al.   Cell Death & Disease

Phase I and Pharmacologic Trial of Cytosine Arabinoside with the Selective Checkpoint 1 Inhibitor Sch 900776 in Refractory Acute Leukemias

(2012) J. E. Karp et al.   CLINICAL CANCER RESEARCH

Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m2 every 21 days in patients with cancer

(2012) Glen J. Weiss et al.   INVESTIGATIONAL NEW DRUGS

Knockdown of PAK4 or PAK1 Inhibits the Proliferation of Mutant KRAS Colon Cancer Cells Independently of RAF/MEK/ERK and PI3K/AKT Signaling

(2012) H. Tabusa et al.   MOLECULAR CANCER RESEARCH

Chk1 inhibition after replicative stress activates a double strand break response mediated by ATM and DNA-dependent protein kinase

(2011) Samuel McNeely et al.   CELL CYCLE

Assessment of Chk1 Phosphorylation as a Pharmacodynamic Biomarker of Chk1 Inhibition

(2011) L. A. Parsels et al.   CLINICAL CANCER RESEARCH

Targeting the S and G2 checkpoint to treat cancer

(2011) Tao Chen et al.   DRUG DISCOVERY TODAY

Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening

(2011) T. J. Guzi et al.   MOLECULAR CANCER THERAPEUTICS

Anticancer therapy with checkpoint inhibitors: what, where and when?

(2011) Michelle D. Garrett et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Histone  H2AX and Poly(ADP-Ribose) as Clinical Pharmacodynamic Biomarkers

(2010) C. E. Redon et al.   CLINICAL CANCER RESEARCH

New Insights into Checkpoint Kinase 1 in the DNA Damage Response Signaling Network

(2010) Y. Dai et al.   CLINICAL CANCER RESEARCH

AACR-FDA-NCI Cancer Biomarkers Collaborative Consensus Report: Advancing the Use of Biomarkers in Cancer Drug Development

(2010) S. N. Khleif et al.   CLINICAL CANCER RESEARCH

Development of a Validated Immunofluorescence Assay for  H2AX as a Pharmacodynamic Marker of Topoisomerase I Inhibitor Activity

(2010) R. J. Kinders et al.   CLINICAL CANCER RESEARCH

The Preclinical Pharmacology and Therapeutic Activity of the Novel CHK1 Inhibitor SAR-020106

(2010) M. I. Walton et al.   MOLECULAR CANCER THERAPEUTICS

Translating cancer research into targeted therapeutics

(2010) J. S. de Bono et al.   NATURE

Context-Dependent Cell Cycle Checkpoint Abrogation by a Novel Kinase Inhibitor

(2010) Andrew J. Massey et al.   PLoS One

Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?

(2009) Craig P. Carden et al.   DRUG DISCOVERY TODAY

Regulation of Chk1

(2009) Claudia Tapia-Alveal et al.   Cell Division

Cyclin B1 is an efficacy-predicting biomarker for Chk1 inhibitors

(2008) Zhan Xiao et al.   BIOMARKERS

G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer

(2008) N Bucher et al.   BRITISH JOURNAL OF CANCER

Chk1 Suppresses a Caspase-2 Apoptotic Response to DNA Damage that Bypasses p53, Bcl-2, and Caspase-3

(2008) Samuel Sidi et al.   CELL

Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1

(2008) A. Blasina et al.   MOLECULAR CANCER THERAPEUTICS

AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies

(2008) S. D. Zabludoff et al.   MOLECULAR CANCER THERAPEUTICS